Last reviewed · How we verify
NCT06611475
Prediction of MMSE Scores for Cognitive Impairment
trial testing MMSE ≤26 in Cognitive Impairment in 693 participants. Completed in 10 November 2024.
10 October 2024
Quick facts
| Lead sponsor | Blekinge Institute of Technology |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 693 |
| Start date | 10 June 2024 |
| Primary completion | 10 October 2024 |
| Estimated completion | 10 November 2024 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- MMSE ≤26
Conditions studied
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Healthy Control — all drugs for Healthy Control →
Sponsor
Blekinge Institute of Technology
Who can join
60 and older, any sex, with Cognitive Impairment or Healthy Control. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore the potential of using machine learning (ML) algorithms to predict cognitive status, specifically MMSE scores, based on oral health and demographic data. The objective is to evaluate the effectiveness of various ML models and identify the most relevant oral health indicators for predicting MMSE scores of 30 (normal cognition) or ≤26 (cognitive impairment) in individuals aged 60 and above.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06611475
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Impairment
Currently open trials in the same condition.
- NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
- NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
- NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
- NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
- NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting
Other Blekinge Institute of Technology trials
Trials by the same sponsor.
- NCT07201610 — Non-invasive Diagnosis of Parkinson's Disease · not yet recruiting
- NCT06705647 — Analyzing Acoustic Properties of the Vowel "a" Collected Via Mobile Phone From Individuals Diagnosed With Chronic Obstru · active not recruiting
- NCT06160674 — Vowel Segmentation for Classification of Chronic Obstructive Pulmonary Disease Using Machine Learning · active not recruiting
- NCT05897944 — Creating and Assessing a Voice Dataset for Automated Classification of Chronic Obstructive Pulmonary Disease · completed
- NCT06011564 — eDENT Oral Health- the Gateway to Quality of Care and Everyday Life at Old Age · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06611475 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Blekinge Institute of Technology
- Last refreshed: 25 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06611475.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing